Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-TEC vs PRP for Patellofemoral Osteoarthritis
NCT06163573Phase 2Recruiting
- Sponsor
- University Hospital Basel
- Start
- Jun 2024
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of rimegepant in patellofemoral osteoarthritis (2 arms), sponsored by University Hospital Basel. Primary endpoint: Knee Injury and Osteoarthritis Outcome Score for pain at 24 months. Started Jun 2024; status: recruiting.
02
Drugs
rimegepant
03
Conditions
patellofemoral osteoarthritis
Beyond the preview
Go deeper on NCT06163573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06163573.